Abstract
Graphene oxide (GO) modified with 29-mer thrombin-binding-aptamer- conjugated gold nanoparticles (TBA29-Au NPs/GO) can synergistically inhibit the thrombin-mediated cleavage of fibrinogen to fibrin. To further improve anticoagulation efficiency in human plasma, TBA29-Au NPs/heparin/GO has been prepared from TBA29-Au NPs/GO and heparin that can also bind thrombin. The dose-dependence of thrombin clotting time (TCT) delay caused by TBA29-Au NPs/heparin/GO is 21.4, 17.0 and >100 times higher than that caused by the TBA29-Au NPs, TBA 29-Au NPs/GO and commercially available drugs (heparin, argatroban, hirudin or warfarin), respectively. This journal is
| Original language | English |
|---|---|
| Pages (from-to) | 1332-1337 |
| Number of pages | 6 |
| Journal | Biomaterials Science |
| Volume | 2 |
| Issue number | 10 |
| DOIs | |
| State | Published - 10 2014 |
| Externally published | Yes |